

28th July 2023

Attention: Ms Kristin Michaels
CEO SHPA, Australia

Dear Ms Michaels,

On behalf of Bristol-Myers Squibb Australia Pty Ltd (BMS) I am writing to inform you of an out of stock situation with the following registered product:

- **Reyataz (atazanavir) 200mg** will be out of stock as of 28th of July 2023 and we do not anticipate resupply until 10th November 2023.
- This has been caused by an unexpected supply issue.
- The TGA have been notified of this today.
- Reyataz 300mg is still available.

If you could please disseminate this information to the SHPA members, that would be appreciated.

If you have questions or require additional information regarding the deletion of this product, please contact the Bristol-Myers Squibb Medical Information Department at 1800 067 567 or via email at: medinfo.australia@bms.com.

Sincerely,



Dr Melinda Munns
Medical Director
Bristol Myers Squibb Australia